関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 4-Piperidinecarboxamide | HCID 3772 | — |
| 反応物 | 3-Bromoanisole | HCID 16971 | — |
| 試薬 | Lithium Hexamethyldisilazide | HCID 2733832 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 触媒 | 2,8,9-Triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo(3.3.3)undecane | HCID 4571243 | — |
| 溶媒 | Toluene | HCID 1140 | — |
| 生成物 | 1-(3-Methoxyphenyl)piperidine-4-carboxamide | HCID 10609747 | 0% |
反応手順
piperidine-4-carboxamide (0.411 g, 3.21 mmol); 1-bromo-3-methoxybenzene (0.339 mL, 2.67 mmol) and diacetoxypalladium (0.120 g, 0.53 mmol) were thoroughly placed under an inert atmoshere. To this was added 2,8,9-triisobutyl-2,5,8,9-tetraaza-1-phosphabicyclo[3.3.3]undecane (0.037 g, 0.11 mmol); LITHIUM BIS(TRIMETHYLSILYL)AMIDE (6.15 mL, 6.15 mmol) and toluene (10 mL). The resultant mixture was stirred at 100 °C overnight. No sign of reaction by LCMS overnight. Abandoned
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-c91f5415f0604adda8f4b73dd97ab0f8 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|
